Fibrobiologics Common Stock Stock Price To Book
| FBLG Stock | 4.23 0.09 2.17% |
FibroBiologics Common Stock fundamentals help investors to digest information that contributes to FibroBiologics Common's financial success or failures. It also enables traders to predict the movement of FibroBiologics Stock. The fundamental analysis module provides a way to measure FibroBiologics Common's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to FibroBiologics Common stock.
FibroBiologics |
FibroBiologics Common Stock Company Price To Book Analysis
FibroBiologics Common's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
FibroBiologics Price To Book Driver Correlations
Understanding the fundamental principles of building solid financial models for FibroBiologics Common is extremely important. It helps to project a fair market value of FibroBiologics Stock properly, considering its historical fundamentals such as Price To Book. Since FibroBiologics Common's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of FibroBiologics Common's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of FibroBiologics Common's interrelated accounts and indicators.
Click cells to compare fundamentals
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, FibroBiologics Common Stock has a Price To Book of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to book for all United States stocks is 100.0% higher than that of the company.
FibroBiologics Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses FibroBiologics Common's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of FibroBiologics Common could also be used in its relative valuation, which is a method of valuing FibroBiologics Common by comparing valuation metrics of similar companies.FibroBiologics Common is currently under evaluation in price to book category among its peers.
FibroBiologics Fundamentals
| Net Income | (16.48 M) | ||||
| Total Debt | 10.57 M | ||||
| Cash Flow From Operations | (6.4 M) | ||||
| Number Of Employees | 10 | ||||
| Total Asset | 11.82 M | ||||
| Retained Earnings | (24.36 M) | ||||
| Working Capital | 32 K | ||||
| Net Asset | 11.82 M |
About FibroBiologics Common Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze FibroBiologics Common Stock's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of FibroBiologics Common using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of FibroBiologics Common Stock based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FANG | Diamondback Energy | |
| CEG | Constellation Energy Corp | |
| ADI | Analog Devices | |
| NXPI | NXP Semiconductors NV | |
| CDNS | Cadence Design Systems |
Additional Information and Resources on Investing in FibroBiologics Stock
When determining whether FibroBiologics Common is a strong investment it is important to analyze FibroBiologics Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics Common's future performance. For an informed investment choice regarding FibroBiologics Stock, refer to the following important reports:Check out FibroBiologics Common Piotroski F Score and FibroBiologics Common Altman Z Score analysis. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics Common. If investors know FibroBiologics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroBiologics Common is measured differently than its book value, which is the value of FibroBiologics that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics Common's market value can be influenced by many factors that don't directly affect FibroBiologics Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.